Evaluation of different total leishmania amazonensis antigens for the development of a first-generation vaccine formulated with a toll-like receptor-3 agonist to prevent cutaneous leishmaniasis

Article

Abstract: BACKGROUND Unfortunately, no any vaccine against leishmaniasis has been developed for human use. The

Palabras claves:

L.Amazonensis, leishmaniasis, Poly (I:C), Whole-cell vaccine

Autores:

Bruna F.A., Cargnelutti D.E., Fernandes A.P., Germanó M.J., Lochedino A.L.S., Lozano E.S., Mackern-Oberti J.P., María Fernanda García Bustos, Salomón M.C., Sanchez M.V.

Fuentes:

scopus